| Literature DB >> 3524824 |
B H Weinerman, E A Eisenhauer, J G Besner, C M Coppin, D Stewart, P R Band.
Abstract
The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of lonidamine, given in an escalating oral daily schedule in patients with measurable advanced renal cell carcinoma. Two responses were seen in 25 evaluable patients. Toxicity was mild or moderate in most patients and included myalgia, nausea, vomiting, somnolence, and testicular pain. Lonidamine was not myelosuppressive. This agent had only minimal activity against renal cell carcinoma when given in this oral schedule.Entities:
Mesh：
Substances：
Year: 1986 PMID： 3524824
Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960